Description

Verosudil is a potent and selective small molecule inhibitor of Rho-associated coiled-coil containing protein kinase (ROCK), specifically developed for ophthalmic applications. This compound matters as a key investigational pharmaceutical ingredient targeting the underlying pathophysiology of elevated intraocular pressure. It is primarily needed by pharmaceutical R&D departments and contract manufacturing organizations (CMOs) engaged in developing next-generation treatments for glaucoma and ocular hypertension. Verosudil CAS NO 1414854-42-4 represents a significant advancement in direct ROCK inhibition therapy.

Application

• Pharmaceutical Active Ingredient (API): Serves as the core active component in ophthalmic drug formulations, primarily for glaucoma.
• Ophthalmic Solution Development: Used in R&D for formulating topical eye drops designed to reduce intraocular pressure by enhancing aqueous humor outflow.
• Preclinical & Clinical Research: Employed as a reference standard in pharmacological studies, toxicity testing, and clinical trials to establish efficacy and safety profiles.
• Mechanistic Studies: Utilized in biochemical and cellular assays to study the ROCK signaling pathway and its role in cytoskeletal dynamics and fibrotic processes.
• Drug Discovery & Development: Acts as a lead compound or benchmark for medicinal chemists developing novel ROCK inhibitors with improved selectivity or pharmacokinetic properties.

Basic Information

Product Name	Verosudil
CAS No.	1414854-42-4
Molecular Formula	C₂₀H₂₅N₅O₃
Molecular Weight	383.45 g/mol
Synonyms	Netarsudil; AR-13324; (S)-4-(3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate; AR13324; Rhopressa (brand name product); ROCK inhibitor AR-13324; 6-[(2S)-2-[[(4-Benzyloxy-2,3-dimethylphenyl)carbonyl]amino]-3-(isoquinolin-6-ylamino)-3-oxopropyl]isoquinolin-5-ol (IUPAC); ATC code S01EX05
EINECS	Contact for details

Quality Control

Our Verosudil is manufactured under strict quality management systems to meet the exacting standards required for pharmaceutical development. Each batch undergoes comprehensive analytical testing, including HPLC for purity and assay, identification by spectroscopic methods (IR, NMR, MS), and stringent control of impurities (related substances, residual solvents, heavy metals). A detailed Certificate of Analysis (COA) is provided with each shipment, ensuring traceability and compliance with ICH guidelines and current Good Manufacturing Practice (cGMP) principles where applicable.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, 15-25°C (59-77°F), in a dry environment. For long-term storage, consider storing under inert atmosphere to maintain stability.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0% (anhydrous basis)
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 1.0% w/w
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.